Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

News Focus

LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Bullboard - Stock Discussion Forum BioVaxys Technology Corp. BVAXF

Primary Symbol: C.BIOV

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical... see more

CSE:BIOV - Post Discussion

BioVaxys Technology Corp. > Level 2 bid ask at 12:45

View:

Post by frankman on Nov 15, 2024 12:45pm

Level 2 bid ask at 12:45

Price	Size	Orders
Ask
0.085	9,000	3
0.08	21,000	2
0.075	35,000	2
0.07	350,450	3
0.065	5,000	1
Bid
0.06	138,634	8
0.055	223,000	10
0.05	145,000	7
0.045	230,000	8
0.04	147,000	11

35

Comment by frankman on Nov 15, 2024 12:48pm

213k traded end of message

24

BioVaxys Technology Corp.

The Market Update

{{currentVideo.title}} {{currentVideo.relativeTime}}

< Previous bulletin

Next bulletin >

A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}

{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}

{{currentVideo.headline}}

{{currentVideo.link1Text}}

{{currentVideo.link2Text}}

< Previous

{{moreVideoText}}

Next >

Dealroom for high-potential pre-IPO opportunities